Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest

Molecular Pharmaceutics

Volumn 10, Issue 1, 2013, Pages 337-352

  Vijayaraghavalu, Sivakumar ^a   Dermawan, Josephine Kamtai ^a   Cheriyath, Venugopalan ^b,c   Labhasetwar, Vinod ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c TEXAS A AND M UNIVERSITY COMMERCE   (United States)

Author keywords

breast cancer; cell cycle analysis; combination therapy; drug resistance; epigenetic drugs; gene expression

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 1; DOXORUBICIN; PROTEIN P21; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DNA METHYLATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BREAST NEOPLASMS; CARCINOGENS; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; G2 PHASE; GENES, TUMOR SUPPRESSOR; HUMANS; HYDROXAMIC ACIDS; INTERNATIONALITY; MCF-7 CELLS;

EID: 84872146371     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3004622     Document Type: Article

References (82)

1. Song, S. H.; Han, S. W.; Bang, Y. J. Epigenetic-based therapies in cancer: progress to date Drugs 2011, 71, 2391-2403
2. Boumber, Y.; Issa, J. P. Epigenetics in cancer: what's the future? Oncology (Williston Park) 2011, 25, 220-226
3. Ellis, L.; Atadja, P. W.; Johnstone, R. W. Epigenetics in cancer: targeting chromatin modifications Mol. Cancer Ther. 2009, 8, 1409-1420
4. Mund, C.; Lyko, F. Epigenetic cancer therapy: Proof of concept and remaining challenges Bioessays 2010, 32, 949-957
5. Teodoridis, J. M.; Strathdee, G.; Brown, R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker Drug Resist. Updates 2004, 7, 267-278
6. Martinez, R. Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events J. Signal Transduction 2012, 10.1155/2012/519807
7. Lo, P. K.; Sukumar, S. Epigenomics and breast cancer Pharmacogenomics 2008, 9, 1879-1902
8. Alelu-Paz, R.; Ashour, N.; Gonzalez-Corpas, A.; Ropero, S. DNA Methylation, Histone Modifications, and Signal Transduction Pathways: A Close Relationship in Malignant Gliomas Pathophysiology J. Signal Transduction 2012, 10.1155/2012/956958
9. Kristensen, L. S.; Nielsen, H. M.; Hansen, L. L. Epigenetics and cancer treatment Eur. J. Pharmacol. 2009, 625, 131-142
10. Gianni, L.; Norton, L.; Wolmark, N.; Suter, T. M.; Bonadonna, G.; Hortobagyi, G. N. Role of anthracyclines in the treatment of early breast cancer J. Clin. Oncol. 2009, 27, 4798-4808
11. Khasraw, M.; Bell, R.; Dang, C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review Breast 2012, 21, 142-149
12. Menna, P.; Paz, O. G.; Chello, M.; Covino, E.; Salvatorelli, E.; Minotti, G. Anthracycline cardiotoxicity Expert Opin. Drug Saf. 2012, 11 (Suppl. 1) S21-S36
13. Octavia, Y.; Tocchetti, C. G.; Gabrielson, K. L.; Janssens, S.; Crijns, H. J.; Moens, A. L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies J. Mol. Cell. Cardiol. 2012, 52, 1213-1225
14. Dusre, L.; Mimnaugh, E. G.; Myers, C. E.; Sinha, B. K. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells Cancer Res. 1989, 49, 511-515
15. Patil, R. R.; Guhagarkar, S. A.; Devarajan, P. V. Engineered nanocarriers of doxorubicin: a current update Crit. Rev. Ther. Drug Carrier Syst. 2008, 25, 1-61
16. Peetla, C.; Bhave, R.; Vijayaraghavalu, S.; Stine, A.; Kooijman, E.; Labhasetwar, V. Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids Mol. Pharmaceutics 2010, 7, 2334-2348
17. Basile, L.; Pignatello, R.; Passirani, C. Active targeting strategies for anticancer drug nanocarriers Curr. Drug Delivery 2012, 9, 255-268
18. Tewey, K. M.; Rowe, T. C.; Yang, L.; Halligan, B. D.; Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 1984, 226, 466-468
19. Kim, R.; Hirabayashi, N.; Nishiyama, M.; Saeki, S.; Toge, T.; Okada, K. Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin Anticancer Res. 1991, 11, 429-431
20. Tan, K. B.; Mattern, M. R.; Eng, W. K.; McCabe, F. L.; Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors J. Natl. Cancer Inst. 1989, 81, 1732-1735
21. Kang, M. R.; Chung, I. K. Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine Mol. Pharmacol. 2002, 61, 879-884
22. Ando, T.; Nishimura, M.; Oka, Y. Decitabine (5-Aza-2-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells Leukemia 2000, 14, 1915-1920
23. Segura-Pacheco, B.; Perez-Cardenas, E.; Taja-Chayeb, L.; Chavez-Blanco, A.; Revilla-Vazquez, A.; Benitez-Bribiesca, L.; Duenas-Gonzalez, A. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine J. Transl. Med. 2006, 4, 32
24. Demircan, B.; Dyer, L. M.; Gerace, M.; Lobenhofer, E. K.; Robertson, K. D.; Brown, K. D. Comparative epigenomics of human and mouse mammary tumors Genes, Chromosomes Cancer 2009, 48, 83-97
25. Daskalakis, M.; Blagitko-Dorfs, N.; Hackanson, B. Decitabine Recent Results Cancer Res. 2010, 184, 131-157
26. Sato, A. Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects OncoTargets Ther. 2012, 5, 67-75
27. Thurn, K. T.; Thomas, S.; Moore, A.; Munster, P. N. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer Future Oncol. 2011, 7, 263-283
28. Wehbe-Janek, H.; Shi, Q.; Kearney, C. M. Cordycepin/Hydroxyurea synergy allows low dosage efficacy of cordycepin in MOLT-4 leukemia cells Anticancer Res. 2007, 27, 3143-3146
29. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing J. R. Stat. Soc. B 1995, 57, 289-300
30. Nikolsky, Y.; Ekins, S.; Nikolskaya, T.; Bugrim, A. A novel method for generation of signature networks as biomarkers from complex high throughput data Toxicol. Lett. 2005, 158, 20-29
31. Mason, C. W.; Swaan, P. W.; Weiner, C. P. Identification of interactive gene networks: a novel approach in gene array profiling of myometrial events during guinea pig pregnancy Am. J. Obstet. Gynecol. 2006, 194, 1513-1523
32. Mahmoud, M. S.; Fujii, R.; Ishikawa, H.; Kawano, M. M. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity Blood 1999, 94, 3551-3558
33. Cheung, A. K.; Ko, J. M.; Lung, H. L.; Chan, K. W.; Stanbridge, E. J.; Zabarovsky, E.; Tokino, T.; Kashima, L.; Suzuki, T.; Kwong, D. L.; Chua, D.; Tsao, S. W.; Lung, M. L. Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-kappaB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 8390-8395
34. Rivenbark, A. G.; Jones, W. D.; Coleman, W. B. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines Lab. Invest. 2006, 86, 1233-1242
35. Shridhar, R.; Zhang, J.; Song, J.; Booth, B. A.; Kevil, C. G.; Sotiropoulou, G.; Sloane, B. F.; Keppler, D. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells Oncogene 2004, 23, 2206-2215
36. Kimura, J.; Kudoh, T.; Miki, Y.; Yoshida, K. Identification of dihydropyrimidinase-related protein 4 as a novel target of the p53 tumor suppressor in the apoptotic response to DNA damage Int. J. Cancer 2011, 128, 1524-1531
37. Waha, A.; Felsberg, J.; Hartmann, W.; von dem Knesebeck, A.; Mikeska, T.; Joos, S.; Wolter, M.; Koch, A.; Yan, P. S.; Endl, E.; Wiestler, O. D.; Reifenberger, G.; Pietsch, T.; Waha, A. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells Cancer Res. 2010, 70, 1689-1699
38. Ueda, K.; Arakawa, H.; Nakamura, Y. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53 Oncogene 2003, 22, 5586-5591
39. Sabatier, R.; Finetti, P.; Adelaide, J.; Guille, A.; Borg, J. P.; Chaffanet, M.; Lane, L.; Birnbaum, D.; Bertucci, F. Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer PLoS One 2011, 6, e27656
40. Baron, V.; Adamson, E. D.; Calogero, A.; Ragona, G.; Mercola, D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin Cancer Gene Ther. 2006, 13, 115-124
41. Drenzek, J. G.; Seiler, N. L.; Jaskula-Sztul, R.; Rausch, M. M.; Rose, S. L. Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines Gynecol. Oncol. 2011, 122, 396-401
42. Yoshimizu, T.; Miroglio, A.; Ripoche, M. A.; Gabory, A.; Vernucci, M.; Riccio, A.; Colnot, S.; Godard, C.; Terris, B.; Jammes, H.; Dandolo, L. The H19 locus acts in vivo as a tumor suppressor Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 12417-12422
43. Sueoka, N.; Lee, H. Y.; Wiehle, S.; Cristiano, R. J.; Fang, B.; Ji, L.; Roth, J. A.; Hong, W. K.; Cohen, P.; Kurie, J. M. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells Oncogene 2000, 19, 4432-4436
44. Rosebeck, S.; Leaman, D. W. Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a Apoptosis 2008, 13, 562-572
45. Ueda, S.; Kuwabara, I.; Liu, F. T. Suppression of tumor growth by galectin-7 gene transfer Cancer Res. 2004, 64, 5672-5676
46. Li, Y.; Basang, Z.; Ding, H.; Lu, Z.; Ning, T.; Wei, H.; Cai, H.; Ke, Y. Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential BMC Cancer 2011, 11, 121
47. Liang, Y.; Van Zant, G. Aging stem cells, latexin, and longevity Exp. Cell Res. 2008, 314, 1962-1972
48. Yan, D. W.; Fan, J. W.; Yu, Z. H.; Li, M. X.; Wen, Y. G.; Li, D. W.; Zhou, C. Z.; Wang, X. L.; Wang, Q.; Tang, H. M.; Peng, Z. H. Downregulation of metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue Biochim. Biophys. Acta 2012, 1822, 918-926
49. Kanda, M.; Nomoto, S.; Okamura, Y.; Nishikawa, Y.; Sugimoto, H.; Kanazumi, N.; Takeda, S.; Nakao, A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis Int. J. Oncol. 2009, 35, 477-483
50. Abbas, T.; Dutta, A. p21 in cancer: intricate networks and multiple activities Nat. Rev. Cancer 2009, 9, 400-414
51. Vaidyanathan, G.; Cismowski, M. J.; Wang, G.; Vincent, T. S.; Brown, K. D.; Lanier, S. M. The Ras-related protein AGS1/RASD1 suppresses cell growth Oncogene 2004, 23, 5858-5863
52. Ijichi, H.; Otsuka, M.; Tateishi, K.; Ikenoue, T.; Kawakami, T.; Kanai, F.; Arakawa, Y.; Seki, N.; Shimizu, K.; Miyazono, K.; Kawabe, T.; Omata, M. Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta Oncogene 2004, 23, 1043-1051
53. Rottapel, R.; Ilangumaran, S.; Neale, C.; La Rose, J.; Ho, J. M.; Nguyen, M. H.; Barber, D.; Dubreuil, P.; de Sepulveda, P. The tumor suppressor activity of SOCS-1 Oncogene 2002, 21, 4351-4362
54. Galm, O.; Yoshikawa, H.; Esteller, M.; Osieka, R.; Herman, J. G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma Blood 2003, 101, 2784-2788
55. Sutherland, K. D.; Lindeman, G. J.; Choong, D. Y.; Wittlin, S.; Brentzell, L.; Phillips, W.; Campbell, I. G.; Visvader, J. E. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas Oncogene 2004, 23, 7726-7733
56. Abeysinghe, H. R.; Pollock, S. J.; Guckert, N. L.; Veyberman, Y.; Keng, P.; Halterman, M.; Federoff, H. J.; Rosenblatt, J. P.; Wang, N. The role of the THY1 gene in human ovarian cancer suppression based on transfection studies Cancer Genet. Cytogenet. 2004, 149, 1-10
57. Lung, H. L.; Bangarusamy, D. K.; Xie, D.; Cheung, A. K.; Cheng, Y.; Kumaran, M. K.; Miller, L.; Liu, E. T.; Guan, X. Y.; Sham, J. S.; Fang, Y.; Li, L.; Wang, N.; Protopopov, A. I.; Zabarovsky, E. R.; Tsao, S. W.; Stanbridge, E. J.; Lung, M. L. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma Oncogene 2005, 24, 6525-6532
58. Ghadjar, P.; Rubie, C.; Aebersold, D. M.; Keilholz, U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer Int. J. Cancer 2009, 125, 741-745
59. Mir, R. A.; Chauhan, S. S. Down regulation of a matrix degrading cysteine protease cathepsin L, by acetaldehyde: role of C/EBPalpha PLoS One 2011, 6, e20768
60. Zhang, J.; Ren, H.; Yuan, P.; Lang, W.; Zhang, L.; Mao, L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells Cancer Res. 2006, 66, 18-23
61. Garg, M.; Kanojia, D.; Seth, A.; Kumar, R.; Gupta, A.; Surolia, A.; Suri, A. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion Eur. J. Cancer 2010, 46, 207-215
62. Kallio, H.; Tolvanen, M.; Janis, J.; Pan, P. W.; Laurila, E.; Kallioniemi, A.; Kilpinen, S.; Tuominen, V. J.; Isola, J.; Valjakka, J.; Pastorekova, S.; Pastorek, J.; Parkkila, S. Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins PLoS One 2011, 6, e27152
63. Blum, C.; Graham, A.; Yousefzadeh, M.; Shrout, J.; Benjamin, K.; Krishna, M.; Hoda, R.; Hoda, R.; Cole, D. J.; Garrett-Mayer, E.; Reed, C.; Wallace, M.; Mitas, M. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer Int. J. Oncol. 2008, 33, 579-584
64. Li, J.; Lau, G.; Chen, L.; Yuan, Y. F.; Huang, J.; Luk, J. M.; Xie, D.; Guan, X. Y. Interleukin 23 Promotes Hepatocellular Carcinoma Metastasis via NF-Kappa B Induced Matrix Metalloproteinase 9 Expression PLoS One 2012, 7, e46264
65. Xu, D. S.; Yang, C.; Proescholdt, M.; Brundl, E.; Brawanski, A.; Fang, X.; Lee, C. S.; Weil, R. J.; Zhuang, Z.; Lonser, R. R. Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival PLoS One 2012, 7, e37811
66. Park, H. J.; Kim, S. R.; Kim, M. K.; Choi, K. S.; Jang, H. O.; Yun, I.; Bae, S. K.; Bae, M. K. Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo Cancer Lett. 2011, 312, 117-127
67. Rohozinski, J.; Anderson, M. L.; Broaddus, R. E.; Edwards, C. L.; Bishop, C. E. Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers PLoS One 2009, 4, e5064
68. Singer, S.; Malz, M.; Herpel, E.; Warth, A.; Bissinger, M.; Keith, M.; Muley, T.; Meister, M.; Hoffmann, H.; Penzel, R.; Gdynia, G.; Ehemann, V.; Schnabel, P. A.; Kuner, R.; Huber, P.; Schirmacher, P.; Breuhahn, K. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer Cancer Res. 2009, 69, 2234-2243
69. Xu, X.; Zur Hausen, A.; Coy, J. F.; Lochelt, M. Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells Int. J. Cancer 2009, 124, 1330-1337
70. Bjelogrlic, S. K.; Radic, J.; Jovic, V.; Radulovic, S. Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice Basic Clin. Pharmacol. Toxicol. 2005, 97, 311-319
71. Petrelli, F.; Borgonovo, K.; Cabiddu, M.; Lonati, V.; Barni, S. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis Breast Cancer Res. Treat. 2012, 135 (2) 335-346
72. Efferth, T.; Giaisi, M.; Merling, A.; Krammer, P. H.; Li-Weber, M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells PLoS One 2007, 2, e693
73. Vijayaraghavalu, S.; Peetla, C.; Lu, S.; Labhasetwar, V. Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions Mol. Pharmaceutics 2012, 9, 2730-2742
74. Gui, C. Y.; Ngo, L.; Xu, W. S.; Richon, V. M.; Marks, P. A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 1241-1246
75. Gray, J.; Cubitt, C. L.; Zhang, S.; Chiappori, A. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer Cancer Biol. Ther. 2012, 13, 614-622
76. Young, J. I.; Sedivy, J. M.; Smith, J. R. Telomerase expression in normal human fibroblasts stabilizes DNA 5-methylcytosine transferase I J. Biol. Chem. 2003, 278, 19904-19908
77. Melixetian, M. B.; Beryozkina, E. V.; Pavlenko, M. A.; Grinchuk, T. M. Altered expression of DNA-topoisomerase IIalpha is associated with increased rate of spontaneous polyploidization in etoposide resistant K562 cells Leuk. Res. 2000, 24, 831-837
78. Walker, J. V.; Nitiss, J. L. DNA topoisomerase II as a target for cancer chemotherapy Cancer Invest. 2002, 20, 570-589
79. Quan, Z. W.; Yue, J. N.; Li, J. Y.; Qin, Y. Y.; Guo, R. S.; Li, S. G. Somatostatin elevates topoisomerase II alpha and enhances the cytotoxic effect of doxorubicin on gallbladder cancer cells Chemotherapy 2008, 54, 431-437
80. Covey, J. M.; Zaharko, D. S. Effects of dose and duration of exposure on 5-aza-2-deoxycytidine cytotoxicity for L1210 leukemia in vitro Cancer Treat. Rep. 1984, 68, 1475-1481
81. Brown, R.; Plumb, J. A. Demethylation of DNA by decitabine in cancer chemotherapy Expert Rev. Anticancer Ther. 2004, 4, 501-510
82. Parise, R. A.; Holleran, J. L.; Beumer, J. H.; Ramalingam, S.; Egorin, M. J. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2006, 840, 108-115